Q2 EPS Forecast for Rigel Pharmaceuticals Raised by Analyst

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Equities researchers at HC Wainwright increased their Q2 2025 earnings per share estimates for shares of Rigel Pharmaceuticals in a research note issued to investors on Wednesday, May 7th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of $2.52 for the quarter, up from their prior estimate of $0.12. HC Wainwright currently has a "Buy" rating and a $57.00 price objective on the stock. The consensus estimate for Rigel Pharmaceuticals' current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals' FY2025 earnings at $3.98 EPS and FY2026 earnings at $2.78 EPS.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.49. Rigel Pharmaceuticals had a net margin of 2.46% and a negative return on equity of 14.80%. The company had revenue of $53.33 million during the quarter, compared to the consensus estimate of $43.87 million. During the same period in the prior year, the business earned ($0.50) earnings per share.

A number of other analysts have also commented on RIGL. B. Riley lifted their price target on Rigel Pharmaceuticals from $20.00 to $24.00 and gave the company a "neutral" rating in a research note on Wednesday, March 5th. Cantor Fitzgerald raised their price objective on shares of Rigel Pharmaceuticals from $20.00 to $23.00 and gave the company a "neutral" rating in a report on Wednesday, May 7th. Citigroup lifted their target price on shares of Rigel Pharmaceuticals from $49.00 to $55.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Finally, StockNews.com cut shares of Rigel Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, March 8th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Rigel Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $36.40.

Rigel Pharmaceuticals Price Performance

RIGL stock traded up $0.05 during midday trading on Friday, reaching $18.34. 144,629 shares of the stock were exchanged, compared to its average volume of 212,963. Rigel Pharmaceuticals has a 52 week low of $7.48 and a 52 week high of $29.82. The company has a fifty day moving average price of $18.51 and a 200 day moving average price of $19.88. The stock has a market capitalization of $327.77 million, a PE ratio of 131.01 and a beta of 1.34.

Hedge Funds Weigh In On Rigel Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. bought a new stake in Rigel Pharmaceuticals in the fourth quarter valued at approximately $63,000. US Bancorp DE lifted its position in shares of Rigel Pharmaceuticals by 57.4% in the 1st quarter. US Bancorp DE now owns 5,120 shares of the biotechnology company's stock worth $92,000 after purchasing an additional 1,868 shares during the period. New York State Common Retirement Fund boosted its stake in shares of Rigel Pharmaceuticals by 65.9% in the 1st quarter. New York State Common Retirement Fund now owns 5,536 shares of the biotechnology company's stock valued at $100,000 after purchasing an additional 2,200 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Rigel Pharmaceuticals by 44.5% during the fourth quarter. Wells Fargo & Company MN now owns 8,603 shares of the biotechnology company's stock worth $145,000 after buying an additional 2,648 shares during the period. Finally, SG Americas Securities LLC increased its position in shares of Rigel Pharmaceuticals by 42.8% during the fourth quarter. SG Americas Securities LLC now owns 9,429 shares of the biotechnology company's stock worth $159,000 after buying an additional 2,827 shares during the period. 66.23% of the stock is currently owned by institutional investors.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.